Califf’s Trial Design Prescription: Less Randomization, More Transparency
Executive Summary
FDA’s new deputy commissioner is expected to advocate for innovation in clinical studies; Duke cardiologist has led numerous trials, including pivotal Xarelto study and Vytorin outcomes trial.
You may also be interested in...
Merck's IMPROVE-IT Study: Will Missing Data, Subgroups Hinder Zetia CV Claim?
FDA asks advisory committee to weigh impact of missing follow-up and 'notable differences' in subgroup treatment effects on company's request for broad cardiovascular benefit claim for Zetia and Vytorin.
FDA Science Board's Report: Legislative Negotiating Tactic, Or Just Whining For Money?
21st Century Cures criticized by FDA advisors for unfunded mandates, but legislation also represents best near-term prospect for reforms of the kind the report envisions.
Hamburg’s Departure Hinged On Selection Of FDA Leadership Team
Medical countermeasures expert Luciana Borio moves to chief scientist role; Hamburg offers preview of the leadership approaches of Stephen Ostroff and Robert Califf.